204 related articles for article (PubMed ID: 35930574)
1. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.
Fekadu G; Yao J; You JHS
PLoS One; 2022; 17(8):e0272770. PubMed ID: 35930574
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
3. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
[TBL] [Abstract][Full Text] [Related]
6. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
[TBL] [Abstract][Full Text] [Related]
7. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
[TBL] [Abstract][Full Text] [Related]
8. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
Ndjeka N; Conradie F; Schnippel K; Hughes J; Bantubani N; Ferreira H; Maartens G; Mametja D; Meintjes G; Padanilam X; Variava E; Pym A; Pillay Y
Int J Tuberc Lung Dis; 2015 Aug; 19(8):979-85. PubMed ID: 26162365
[TBL] [Abstract][Full Text] [Related]
9. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
Fan Q; Ming WK; Yip WY; You JHS
Int J Infect Dis; 2019 Jan; 78():44-49. PubMed ID: 30342251
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
12. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
[TBL] [Abstract][Full Text] [Related]
13. Standard diagnostics with and without urine-based lipoarabinomannan testing for tuberculosis disease in HIV-infected patients in a high-burden setting-A cost-effectiveness analysis.
Fekadu G; Wang Y; You JHS
PLoS One; 2023; 18(7):e0288605. PubMed ID: 37450476
[TBL] [Abstract][Full Text] [Related]
14. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
[No Abstract] [Full Text] [Related]
15. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
[TBL] [Abstract][Full Text] [Related]
16. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
[TBL] [Abstract][Full Text] [Related]
17. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
Barvaliya SV; Desai MK; Panchal JR; Solanki RN
Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea.
Park HY; Ku HM; Sohn HS; Seo HS; Yung Lee H; Hwa Lim K; Kwon JW
Clin Ther; 2016 Mar; 38(3):655-67.e1-2. PubMed ID: 26907504
[TBL] [Abstract][Full Text] [Related]
19. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
[TBL] [Abstract][Full Text] [Related]
20. Bedaquiline: Current status and future perspectives.
Khoshnood S; Goudarzi M; Taki E; Darbandi A; Kouhsari E; Heidary M; Motahar M; Moradi M; Bazyar H
J Glob Antimicrob Resist; 2021 Jun; 25():48-59. PubMed ID: 33684606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
